Weight-loss drugs linked to rare eye condition in massive data review
A comprehensive analysis of nearly 1.6 million patients suggests that popular diabetes and obesity medications may increase the risk of a rare condition that causes sudden vision loss, though the absolute risk remains very low.
A recent meta-analysis of medical data has revealed a potential link between weight-loss drugs and a rare eye condition known as nonarteritic anterior ischemic optic neuropathy. The study, published in Neurology, found that patients using semaglutide, a popular weight-loss and diabetes medication, experienced sudden vision loss at a higher rate compared to those using other treatments.
This condition, which involves restricted blood flow to the optic nerve, can result in permanent visual damage. The researchers pooled data from five studies involving a massive sample of 1,593,554 patients, with 682,456 using semaglutide and 911,098 using other drugs. The findings highlight the importance of identifying rare side effects of widely prescribed medications, as millions of patients now take these drugs globally.
Brief written by urgent.news from PsyPost's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
